Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer

Por Bastholt, Lars, Kreissl, Michael C., Führer, Dagmar, Maia, Ana L., Locati, Laura D., Maciel, Léa, Wu, Yi, Heller, Kevin N., Webster, Alan, Elisei, Rossella
Publicado no Eur Thyroid J (2016)

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

Por Douillard, Jean-Yves, Ostoros, Gyula, Cobo, Manuel, Ciuleanu, Tudor, Cole, Rebecca, McWalter, Gael, Walker, Jill, Dearden, Simon, Webster, Alan, Milenkova, Tsveta, McCormack, Rose
Publicado no J Thorac Oncol (2014)

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

Por Nilsson, Monique B., Giri, Uma, Gudikote, Jayanthi, Tang, Ximing, Lu, Wei, Tran, Hai, Fan, Youhong, Koo, Andrew, Diao, Lixia, Tong, Pan, Wang, Jing, Herbst, Roy, Johnson, Bruce E., Ryan, Andy, Webster, Alan, Rowe, Philip, Wistuba, Ignacio I., Heymach, John V.
Publicado no Clin Cancer Res (2015)